长读长KIR基因分型揭示供者KIR/HLA多态性与T细胞肿瘤移植后复发相关
研究采用高分辨率长读长分型对15个KIR基因进行供者KIR/HLA分析,在219例接受异基因造血干细胞移植的T细胞白血病/淋巴瘤患者中无偏发现复发相关组合,并在独立队列验证。低危组合供者与复发降低和总生存改善相关,该关联见于其他T细胞肿瘤但不见于急性髓系白血病,提示疾病特异性,支持基于KIR/HLA的供者选择。
要点
- KIR3DL1∗005或KIR3DS1∗013伴HLA-B-D2-62E、KIR3DL1∗001/∗007/∗015/∗020伴HLA-B-D2-62V为高危组合。
- 低危组合供者较L-/H+供者复发降低(校正HR 0.36,95%CI 0.19-0.65,P=7.5×10-4)且总生存改善。
- 低危组合可增强KIR3DL1+ NK细胞对HLA I类缺失靶细胞的CD107a脱颗粒,支持NK细胞教育增强。
核心结论
- 供者KIR/HLA氨基酸水平组合与T细胞白血病/淋巴瘤异基因移植后复发风险相关,低危组合与复发降低和总生存改善相关,支持基于KIR/HLA的供者选择。
研究设计与样本
- 对219例接受allo-HSCT的T细胞白血病/淋巴瘤(ATL)患者行15个KIR基因的高分辨率长读长分型,进行无偏发现分析并在独立队列验证。
- 分析供者KIR/HLA氨基酸水平组合与复发风险的关联,并考虑KIR单倍型间的连锁不平衡。
主要发现
- 与L-/H+供者(n=119)相比,L+/H-、L-/H-和L+/H+供者(n=80)复发降低(校正HR 0.36;95%CI 0.19-0.65;P=7.5×10-4)且总生存改善(校正HR 0.67;95%CI 0.45-0.98;P=.038)。
- 上述供者与其他T细胞肿瘤复发降低相关(n=145;校正HR 0.37;95%CI 0.16-0.89;P=.026),但在急性髓系白血病中无关联(n=965;P=.77)。
- 低危组合增加KIR3DL1+ NK细胞对HLA I类缺失靶细胞的CD107a脱颗粒,符合NK细胞教育增强。
关键数值与推荐
- 高危(H)组合:KIR3DL1∗005或KIR3DS1∗013伴HLA-B α2结构域第62位谷氨酸(HLA-B-D2-62E);KIR3DL1∗001/∗007/∗015/∗020伴HLA-B-D2-62V(缬氨酸)。
- 低危(L)组合:KIR3DL1∗015伴HLA-B α1结构域第80位异亮氨酸(HLA-B-D1-80I);KIR3DL1∗001/∗005/∗007/∗020伴HLA-B-D1-80T(苏氨酸)。
临床怎么用
- 在T细胞白血病/淋巴瘤异基因移植供者选择时可参考供者KIR/HLA氨基酸组合,优先低危组合以降低复发风险。
- 该供者选择策略可能不适用于急性髓系白血病,应用时需考虑疾病特异性。
局限性
- 发现队列为ATL患者219例,其他T细胞肿瘤与急性髓系白血病为验证性分析,样本量相对有限。
- 研究为关联分析,KIR/HLA组合与复发的因果关系及临床干预价值尚需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Donor polymorphisms in killer-cell immunoglobulin-like receptor (KIR) and HLA shape natural killer (NK) cell activity, which may influence relapse risk after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, association studies have been limited by insufficient allele-level KIR genotyping. Using high-resolution, long-read genotyping of 15 KIR genes, we performed an unbiased discovery analysis in 219 patients with T-cell leukemia/lymphoma (ATL) who underwent allo-HSCT to identify relapse-associated donor KIR/HLA polymorphisms. We comprehensively tested associations between donor KIR/HLA amino acid-level combinations and relapse risk, accounting for linkage disequilibrium across KIR haplotypes, and validated the findings in independent cohorts. In ATL, KIR3DL1∗005 or KIR3DS1∗013 with glutamic acid at position 62 in the HLA-B α2 domain (HLA-B-D2-62E) and KIR3DL1∗001/∗007/∗015/∗020 with HLA-B-D2-62V (valine) were high-risk (H) combinations. Meanwhile, KIR3DL1∗015 with isoleucine at position 80 in the HLA-B α1 domain (HLA-B-D1-80I) and KIR3DL1∗001/∗005/∗007/∗020 with HLA-B-D1-80T (threonine) were low-risk (L) combinations. Compared with L-/H+ donors (n = 119), L+/H-, L-/H-, and L+/H+ donors (n = 80) showed reduced relapse (adjusted hazard ratio [HR], 0.36; 95% confidence interval [CI], 0.19-0.65; P = 7.5 × 10-4) and improved overall survival (adjusted HR, 0.67; 95% CI, 0.45-0.98; P = .038). Those donors were associated with reduced relapse in other T-cell malignancies (n = 145; adjusted HR, 0.37; 95% CI, 0.16-0.89; P = .026) but not in acute myeloid leukemia (n = 965; P = .77), suggesting disease specificity. Low-risk combinations increased CD107a degranulation of KIR3DL1+ NK cells against HLA class I-deficient targets, consistent with enhanced NK cell education. These findings support KIR/HLA-based donor selection and underscore the role of antitumor NK cell immunity.
引用
- Morita M, Kawaguchi S, Shindo T, et al. Long-read KIR genotyping reveals donor KIR/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies. Blood Adv. 2026. PMID: 41995743. doi:10.1182/bloodadvances.2025019066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。